Davis Polk advises AstraZeneca on $15b spin-off and merger
IFLR is part of the Delinian Group, Delinian Limited, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 00954730
Copyright © Delinian Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Davis Polk advises AstraZeneca on $15b spin-off and merger

Pharmaceuticals business AstraZeneca has chosen the same lawyers that worked on its recent merger to advise on the company's next step, a deal valued at $15 billion.

Unlock this content.

The content you are trying to view is exclusive to our subscribers.

To unlock this content:

Take a Free Trial or Login
Gift this article